Albert Hu: Okay. Thank you. So the government, especially — or they’re more vocal, especially after the pandemic about the need for to prevent antibiotic resistant bacteria spread. So is there a pathway to potentially working with the CDC or HHS to help enforce a requirement to need a Pheno like solution at all?
Jack Phillips: Yes. Thanks for that question. And so absolutely, you highlighted that the CDC has made this a major priority. They refer to this is the silent pandemic, and they continue to work on this. I would say that they recently — actually recently had a meeting of many members of industry, and we were part of this in — at the CDC. Our Head of Strategy and Marketing attended the meeting along with several other members of the industry, and it was really all about continuing to focus on how we can really address AMR, ultimately address sepsis and doing it from a diagnostic perspective by providing rapid diagnostic testing for susceptibility to get patients on the right therapy much quicker. And so yes, it’s a big focus. It continues to be a focus, and we continue to work with the CDC.
Albert Hu: Great. Thanks. And can you provide us just some color on the competitive environment for rapid microbiology systems?
Jack Phillips: Yes. I mean it’s — I think, again, I always say this. I mean competition is a good thing. I mean it’s really — it really helps to elevate the need for a change in the current methods of diagnosing and providing antibiotic susceptibility testing. Today, that testing is completely inadequate with the turnaround times and so forth and patients are suffering. And so with that, there’s obviously a lot of focus in this area, and there’s — there’s several competitors that are coming to market, looking to get approved on market. I won’t get into naming names and so forth. But we still believe, though, as we look at the offering from a menu standpoint, as we look at turnaround times, as we look at not only the menu but also limitations associated with that — those menus.
The Pheno is still a proven diagnostic solution and will continue to be very competitive with the emerging players that are coming to market. And then obviously, as we look beyond positive blood, Wave is going to be a whole another story because Wave obviously take us not only into positive blood, but into the isolate market as well. And as I mentioned there, most of the platforms in the isolate market are 30 and 40 years old and really provide much slower turnaround time than what we’ll be looking at doing with Wave.
Albert Hu: Okay. Awesome. And last question us. So, we heard some positive commentary on the BD partnership last quarter. But do you think we would see the BD partnership materially — when do you think we would see the BD partnership materially boost the installed bases?
Jack Phillips: Yes. I mean it’s a fair question. We had a better quarter — last quarter, we had a better quarter than this quarter in new contracted deals. I would say — and it was actually one of the best quarters we’ve had since 2021. So, we did several new contracted customers then. This quarter was less than that. Clearly — but again, it’s hard to say exactly, but the velocity in the funnel and the number of opportunities continues to increase. And while BD continues to work on their forecast, they just — they kicking their year off and they’re training their salespeople, they have sales meetings ongoing. And Pheno and Arc outside of the US is a focus of their sales team and a big part of their BSI campaign. And so we expect to continue to see improvement quarter-over-quarter on the number of new opportunities that BD is bringing in.
Albert Hu: Okay. Thank you,
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Mr. Jack Phillips for closing remarks.
